NasdaqGS - Delayed Quote USD

Gritstone bio, Inc. (GRTS)

Compare
0.0472 -0.0048 (-9.23%)
At close: October 18 at 4:00 PM EDT
0.0452 -0.00 (-4.24%)
After hours: October 18 at 7:59 PM EDT
Loading Chart for GRTS
DELL
  • Previous Close 0.0520
  • Open 0.0505
  • Bid --
  • Ask --
  • Day's Range 0.0460 - 0.0513
  • 52 Week Range 0.0460 - 3.1700
  • Volume 33,856,646
  • Avg. Volume 15,735,549
  • Market Cap (intraday) 5.575M
  • Beta (5Y Monthly) 0.50
  • PE Ratio (TTM) --
  • EPS (TTM) -1.0900
  • Earnings Date Nov 6, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 0.75

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors. The company is also developing SLATE, an off-the-shelf immunotherapy candidate, which is in Phase 2 clinical trials for the treatment of metastatic solid tumors. In addition, it develops CORAL, a COVID-19 vaccine program; and a therapeutic vaccine candidate that is in Phase 1 clinical trials designed to treat and cure human immunodeficiency virus (HIV) infection. Gritstone bio, Inc. has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California. On October 10, 2024, Gritstone bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.

gritstonebio.com

231

Full Time Employees

December 31

Fiscal Year Ends

Recent News: GRTS

View More

Performance Overview: GRTS

Trailing total returns as of 10/18/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

GRTS
97.69%
S&P 500
22.95%

1-Year Return

GRTS
97.79%
S&P 500
34.10%

3-Year Return

GRTS
99.49%
S&P 500
31.16%

5-Year Return

GRTS
99.43%
S&P 500
95.62%

Compare To: GRTS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: GRTS

View More

Valuation Measures

Annual
As of 10/18/2024
  • Market Cap

    5.57M

  • Enterprise Value

    52.36M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    11.76

  • Price/Book (mrq)

    0.25

  • Enterprise Value/Revenue

    105.56

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -46.71%

  • Return on Equity (ttm)

    -201.94%

  • Revenue (ttm)

    14.61M

  • Net Income Avi to Common (ttm)

    -133.03M

  • Diluted EPS (ttm)

    -1.0900

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    55.71M

  • Total Debt/Equity (mrq)

    461.91%

  • Levered Free Cash Flow (ttm)

    -66.16M

Research Analysis: GRTS

View More

Company Insights: GRTS

Research Reports: GRTS

View More

People Also Watch